Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which iron pill is kinder to blood donors?

NCT ID NCT05678647

Symptom relief Sponsor: Uppsala University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two different oral iron supplements given to regular blood donors after donation. One is a newer form called sucrosomial iron (SiderAl Forte) and the other is standard iron sulfate (Duroferon). The goal was to see which one causes fewer side effects and whether it helps with restless legs symptoms. 120 donors participated, and the results will help guide which supplement is better tolerated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sucrosomial iron (SiderAl Forte) and iron sulfate (Duroferon)
What this could lead to
If one supplement causes fewer side effects, it could become the preferred option for blood donors needing iron replacement.
What could go wrong
This is a small, completed trial with only 120 participants, so results may not apply to all donors. Side effects are still possible with either supplement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Jan 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Blood donors at Uppsala University hospital wo have been donating blood regularly the last two years are eligible to participate in the study. Exclusion Criteria: Donors who cannot be accepted for blood donation anymore because they do not fulfill the Swedish criteria for blood donation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood donation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood donation

Contacts and locations

Locations

  • Clinical Immunology and Transfusion Medicine, Uppsala University Hospital

    Uppsala, 75237, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.